Evidence map›Paper›PMID 28283830›Full record

Trial reportEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017

Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial.

A Dinh, B Davido, M Etienne, F Bouchand, A Raynaud-Lambinet, E Aslangul-Castier, T A Szwebel, C Duran, G Der Sahakian, C Jordy and 6 more

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 34 citations in OpenAlex.

  1. Improving effective antimicrobial resistance (AMR) prevention in ambulatory care: lessons from secondary appraisal of Belgian anti-infectious treatment care guidelines.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  2. Reply to Bulloch.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  3. Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Observational
  4. Article
  5. White paper on antimicrobial stewardship in solid organ transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

A DinhInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint-Quentin University, 104 Bd Raymond Poincaré, 92380, Garches, France. aurelien.dinh@aphp.fr.ORCID http://orcid.org/0000-0002-5843-4819
B DavidoInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint-Quentin University, 104 Bd Raymond Poincaré, 92380, Garches, France.
M EtienneInfectious Disease Department, Rouen University Hospital, 1 Rue de Germont, 76031, Rouen, France.
F BouchandPharmacy Department, Raymond Poincaré University Hospital, AP-HP, Versailles Saint-Quentin University, 104 Bd Raymond Poincaré, 92380, Garches, France.
A Raynaud-LambinetEmergency Department, Toulouse Rangueil University Hospital, 1, Avenue du Professeur Jean Poulhès, 31050, Toulouse, France.
E Aslangul-CastierInternal Medicine Department, Hotel-Dieu University Hospital, 1 Place du Parvis de Notre-Dame, 75004, Paris, France.
T A SzwebelEmergency Department, Hotel-Dieu University Hospital, 1 Place du Parvis de Notre-Dame, 75004, Paris, France.
C DuranInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint-Quentin University, 104 Bd Raymond Poincaré, 92380, Garches, France.
G Der SahakianEmergency Department, Hotel-Dieu University Hospital, 1 Place du Parvis de Notre-Dame, 75004, Paris, France.
C JordyEmergency Department, Versailles Hospital, 177 Rue de Versailles, 78150, Le Chesnay, France.
X RanchouxEmergency Department, Versailles Hospital, 177 Rue de Versailles, 78150, Le Chesnay, France.
N SembachEmergency Department, University HEGP Hospital, 20 Rue Leblanc, 75015, Paris, France.
E MathieuEmergency Department, Foch Hospital, 40 Rue Worth, 92151, Suresnes, France.
A DavidoEmergency Department, University HEGP Hospital, 20 Rue Leblanc, 75015, Paris, France.
J SalomonInfectious Disease Unit, Raymond Poincaré University Hospital, AP-HP, Versailles Saint-Quentin University, 104 Bd Raymond Poincaré, 92380, Garches, France.
L BernardInfectious Disease Department, Bretonneau University Hospital, Rabelais University, 2 Boulevard Tonnellé, 37000, Tours, France.
Assistance Publique – Hôpitaux de Paris · FRHôpital André Mignot · FRHôpital Européen Georges-Pompidou · FRHôtel-Dieu de Paris · FRCentre d'Immunologie et des Maladies Infectieuses · FRCentre Hospitalier Universitaire de Rouen · FRCentre Hospitalier Universitaire de Toulouse · FRHotel Dieu Hospital · CAInserm · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment duration of acute uncomplicated pyelonephritis (AUP) is still under debate. As shortening treatment duration could be a means to reduce antimicrobial resistance, we aimed to establish whether 5 days of antibiotic treatment is non-inferior to 10 days in patients with AUP. We performed an open-label prospective randomized trial comparing 5 days to 10 days of fluoroquinolone treatment for AUP. The inclusion criteria were: female patients aged ≥18 years with clinical signs of urinary tract infection, fever >38 °C, and positive urinalysis. Patients were randomized to either 5 or 10 days of fluoroquinolone treatment. Outcome was cure at day 10 and day 30 after the end of treatment. One hundred patients were randomized and 12 were excluded after randomization. The mean ± standard deviation (SD) age was 31.8 ± 11 years old and the mean ± SD temperature was 38.6 ± 0.7 °C. The main bacterium involved was Escherichia coli (n = 86; 97.7%) and 3 (3.4%) patients had a positive blood culture. In the post-hoc analysis, clinical cure 10 days after the end of the treatment was 28/30 (93.3%) in the 5-day arm and 36/38 (94.7%) in the 10-day arm (p = 1.00). At day 30, the clinical cure rate was 23/23 (100%) in the 5-day arm and 20/20 (100%) in the 10-day arm (p = 1.00). The microbiological cure rate was 20/23 (87.0%) in the 5-day arm and 16/20 (80.0%) in the 10-day arm (p = 1.00). The efficacy of 5 days of fluoroquinolone treatment does not seem different from 10 days of treatment for AUP.

Indexed as

Administration, OralAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsEscherichia coli InfectionsFemaleFluoroquinolonesHumansMiddle AgedProspective StudiesPyelonephritisTime FactorsTreatment OutcomeYoung AdultAnti-Bacterial AgentsFluoroquinolones

Identifiers

PMID28283830
OpenAlexW2593576576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.